Benlysta belimumab: Phase III started

Human Genome said in May 2011 partner GlaxoSmithKline began a double-blind, placebo-controlled, Asian Phase III trial to evaluate 10 mg/kg IV Benlysta plus standard of care every 2 weeks for the firs...